Clinical	O
outcome	O
assessment	O

The	O
patients	O
were	O
observed	O
for	O
2	O
weeks	O
after	O
hUC	O
-	O
MSC	O
infusion	O
,	O
and	O
clinical	O
symptoms	O
,	O
laboratory	O
tests	O
,	O
and	O
radiological	O
results	O
were	O
recorded	O
and	O
confirmed	O
by	O
experienced	O
physicians	O
.	O

The	O
primary	O
clinical	O
outcomes	O
included	O
the	O
incidence	B-PrimaryOutcome
of	I-PrimaryOutcome
progression	I-PrimaryOutcome
from	I-PrimaryOutcome
severe	I-PrimaryOutcome
to	I-PrimaryOutcome
critical	I-PrimaryOutcome
illness	I-PrimaryOutcome
and	O
the	O
time	B-PrimaryOutcome
to	I-PrimaryOutcome
a	I-PrimaryOutcome
clinical	I-PrimaryOutcome
improvement	I-PrimaryOutcome
of	I-PrimaryOutcome
two	I-PrimaryOutcome
points	I-PrimaryOutcome
on	I-PrimaryOutcome
a	I-PrimaryOutcome
seven	I-PrimaryOutcome
-	I-PrimaryOutcome
category	I-PrimaryOutcome
ordinal	I-PrimaryOutcome
scale	O
that	O
has	O
been	O
used	O
widely	O
in	O
clinical	O
symptom	O
assessment	O
or	O
discharge	O
from	O
the	O
hospital	O
[	O
27	O
]	O
.	O

In	O
our	O
study	O
,	O
the	O
NEWS2	O
score	O
and	O
seven	O
-	O
category	O
ordinal	O
scale	O
were	O
used	O
to	O
assess	O
the	O
clinical	O
symptoms	O
and	O
conditions	O
of	O
the	O
enrolled	O
patients	O
[	O
28	O
]	O
.	O

The	O
secondary	O
clinical	O
outcomes	O
included	O
patient	B-SecondaryOutcome
status	I-SecondaryOutcome
at	B-TimeFrame
days	I-TimeFrame
7	I-TimeFrame
and	I-TimeFrame
14	I-TimeFrame
assessed	O
with	O
a	O
seven	O
-	O
category	O
ordinal	O
scale	O
,	O
hospital	B-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
changes	B-SecondaryOutcome
in	I-SecondaryOutcome
oxygenation	I-SecondaryOutcome
index	I-SecondaryOutcome
,	O
hematological	B-SecondaryOutcome
inflammatory	I-SecondaryOutcome
factors	I-SecondaryOutcome
,	O
and	O
imaging	B-SecondaryOutcome
.	O

